ClinicalTrials.gg
CompletedNCT03380312Updated Sep 19, 2024

MRI Imaging of Ipsilateral Retromuscular Access

An observational study in Hernia, Incisional, sponsored by Filip Muysoms. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Filip Muysoms · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to measure the mesh shrinkage and the visualization of the mesh with MRI scan at 1 month and 13 months after robot assisted retromuscular incisional hernia repair with ipsilateral access and the use of the visible CICAT mesh (Dynamesh®) for defect repair. The investigators also want to measure the volume of the rectus muscles and the change between 1 and 13 months.

Read the detailed description

The aim of this study is to measure the mesh shrinkage and the visualization of the mesh with MRI scan at 1 month and 13 months after robot assisted retromuscular incisional hernia repair with ipsilateral access and the use of the visible CICAT mesh (Dynamesh®) for defect repair. The investigators also want to measure the volume of the rectus muscles and the change between 1 and 13 months. Possibly the ipsilateral retromuscular access could induce some atrophy of the rectus muscles.

The study will be conducted in the department of surgery in het AZ Maria Middelares, Ghent, Belgium. Dr. Filip Muysoms will personally select and operate all patients eligible for this study. Dr.Muysoms will inform all patients about the surgery and the follow-up with MRI scan thereafter. Dr. Beckers and Dr. Heindryckx will perform all MRI examinations of the patients at 1 month and 13 months post-operatively and will be available for questions from the patient.

The investigators want to show that with this type of mesh it is possible to visualize the mesh after retromusculare placement in vivo in a safe manner. Furthermore, the positioning of the mesh, mesh shrinkage or mesh shifting will be monitored with this technique. This provides long-term benefit and provides early treatment possibilities in case of post-operative complications related to the mesh position.

02

Conditions studied

  • Hernia, Incisional

Browse trials for

03

In context

Incisional Hernia

212 studies on the registry are indexed under Incisional Hernia; 58 are open to participants now.

This study's enrollment of 20 is below the median of 150 across 75 observational studies indexed under Incisional Hernia.

Browse Incisional Hernia studies →

Lead sponsor

Filip Muysoms is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients scheduled for robot assisted laparoscopic retromuscular repair (rTARUP =robotic Trans Abdominal Retromuscular Umbilical Prosthesis) of a midline ventral hernia will be invited to take part in the study. Both primary ventral and incisional midline hernias will be included (EHS classification M1-M5).

A total of 20 patients will be enrolled in this observational study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 patients selected and operated by PI.

Exclusion criteria

Exclusion Criteria:

  • \<18 years
  • Emergency surgery (incarcerated hernia)
  • Clean-contaminated, contaminated or dirty procedures (according to the CDC classification)
  • Lateral hernias
  • Hernias that need a component separation technique.
  • Previous mesh repair on the midline
  • > 4
  • Pregnancy
  • No patient
  • of less than 2years
  • for MRI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Interventions

  • ProcedurerTARUP technique

    robot-assisted rTARUP technique

06

What researchers measure

Primary outcomes

  1. Change of the mesh surface (percentage)

    Shrinkage rate / change of the mesh surface (percentage) as measured with the MRI between 1 month and 13 months postoperatively, defined as (100 - mesh surface at 13 months x 100 / mesh surface at 1 month)

    Time frame: 1 month and 13 month post-operatively

Secondary outcomes

  1. Change in mesh surface between implantation surface size

    Change in mesh surface between implantation surface size, surface at 1m and at 13m

    Time frame: 1 month and 13 month post-operatively

  2. Change in mesh width and length between implantation surface size

    Change in mesh width and length between implantation surface size, surface at 1m and at 13m

    Time frame: 1 month and 13 month post-operatively

  3. Volume of the rectus muscle at the level of the umbilicus

    Volume of the rectus muscle at the level of the umbilicus on both sides at 1m and at 13m

    Time frame: 1 month and 13 month post-operatively

  4. Operation duration

    recording of the operation duration needed for robo-assisted TARUP

    Time frame: once during operation

  5. Intra-operative complications

    Intra-operative complications registered until 4 weeks after the hernia repair

    Time frame: until 4 weeks post-operative

  6. Early post-operative complications

    Early post-operative complications detected until 30 days after hernia repair

    Time frame: until 30 days post-operative

  7. Late complications

    Late complications (after 30 days)

    Time frame: after 30 days post-operative

  8. Quality of Life questionnaire

    A questionnaire will be used to measured life quality of the participants preoperatively and at 1m and 13m postoperatively

    Time frame: preoperative and 1 month and 13 month post-operatively

07

Study locations

1 site
  • AZ Maria Middelares
    Ghent, 9000, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jun 2021, 44 months.

Of 24 observational studies under Incisional Hernia, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 61. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2017
First posted
Dec 21, 2017
StartActual
Sep 26, 2017
Primary completionActual
Jun 19, 2021
CompletionActual
Jan 19, 2022
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03380312
Lead sponsor
Filip Muysoms
Responsible party
Filip Muysoms (Surgeon, Algemeen Ziekenhuis Maria Middelares) — Sponsor-investigator
First posted
Dec 21, 2017
Start date
Sep 26, 2017
Primary completion
Jun 19, 2021
Completion
Jan 19, 2022
Last update
Sep 19, 2024

Study contacts

Filip Muysoms, MD,PhD
principal investigator · Algemeen Ziekenhuis Maria Middelares

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion